Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Pemetrexed and Cisplatin in First-Line EGFR-Negative Non-Squamous NSCLC
NCT03671538Phase 2Unknown
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03671538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671538.